Lundin Mining Corp. (LUNMF.PK)
Q2 2010 Earnings Call
July 28, 2010 10:00 am ET
Geron Corporation Q2 2010 Earnings Call Transcript
iShares Gold ETF Slashes Fees, Sees Results
Tom Lydon submits:
ETFs are cheap, but that doesn’t mean they’re not getting cheaper. One gold fund provider is engaging in a good old-fashioned price war to entice gold traders to its side of the camp, and it appears to be working.
On July 1, BlackRock lowered the annual expenses on its gold ETF the iShares Comex Gold Trust ETF (IAU) to 0.25% from 0.40%, writes William Baldwin for Forbes. Market leader in gold ETFs, State Street-managed SPDR Gold Shares ETF (GLD) is maintaining its 0.40% expense ratio.
First Solar Beats, Raises Guidance; Shares Plunge
Avanir’s STAR Trial: Offering Clarity to the FDA
Sheff Station submits:
In early 2006, Avanir (AVNR) filed a drug application for Zenvia. It had filed a submission for Zenvia with the 30/30 dose combination. Two Phase III studies demonstrated safety and efficacy of Zenvia in PBA as well as 10 clinical trials. Priority review was received from the FDA as they acknowledged it’s a disorder with a high unmet medical need. In late 2006 AVNR received an approvable letter from the FDA.
The primary concern of the FDA was QT prolongation. The focus was not on the original therapeutic dose of Zenvia (that included 30mg quinidine) but the thorough QT study where the FDA concentrated on the supratherapeutic dose which was a 60/60 combination. The FDA saw a linear relationship in QT prolongation from the 60/60 combination. As the dose went from 30/30 BID to 60/60 BID there was almost a 2 times increase in QT prolongation. The FDA was concerned that with dosing errors, or drug to drug interactions, that many patients would have the QT risk associated with the 60/60 supratherapeutic dose.
Acme United: Undervalued and Overlooked
Adam Sues submits:
Acme United Corp (ACU), a supplier of cutting, measuring and safety products, reported 2nd quarter results this week. ACU is another small undervalued stock in a boring business line that has been overlooked by the market.
The stock was hit hard during the recession, and is slowly starting to regain its 2006-2008 levels.
Chinese Demand Should Boost These Three Clean Energy ETFs
ETF Database submits:
Around the world, stock markets have been very rocky as of late with investors fearing a return to a recession in many developed countries. This fear has compounded with weak earnings out of many large banks and tempered growth predictions for mainland China to reduce expectations for one of the main drivers of growth in the emerging world. The government has stepped in to cool down the red-hot Chinese economy in order to avoid inflationary pressures but still keep the economy growing at an acceptable rate. This has forced China to end a variety of stimulus programs and forcing banks to cut down on their lending. Chinese banks issued 36 billion yuan less in loans for the month of June and the government has set a target of 7.5 trillion yuan in loans for the year, a 22% decrease from 2009 levels. Due to this sharp cut in available loans, it looks likely that many Chinese sectors will not be able to grow as quickly as they have been in previous quarters as growth looks likely to fall back below the 10% mark for the next quarter.
Despite the slightly lowered prospects for growth in the overall market, the energy sector looks to attract an out-sized percentage of investment going forward. China has now become the world’s largest energy consumer, surpassing the U.S. for the first time since the statistics first began. While ten to twenty years ago this event would have been met with fanfare in China as another symbol of their growing industrial might, Chinese leaders have downplayed the news saying that the report was flawed and inaccurate with one Chinese official saying that “the IEA’s data on China’s energy use is unreliable” . This shows just how far the world has come in terms of attitudes on energy usage in just a few short years, leaving the Chinese scrambling to come up with a variety of new technologies and ideas in order to help reduce the country’s dependence on oil and coal while still allowing the economy to grow unimpeded by energy issues.
Jazz: Your FDA Panel Primer
Rockford Coscia submits:
Jazz Pharmaceuticals (JAZZ) is a small biotech firm specializing in treatments for neurology and psychiatry patients. Jazz has two products currently being marketed in the U.S.: Xyrem for the treatment of narcolepsy, and Luvox CR for the treatment of social anxiety disorder and obsessive compulsive disorder. Currently, a new drug application is under review for Jazz’s fibromyalgia therapy currently referred to as JZP-6.
As part of the evaluation process, the FDA has scheduled a panel, in which it consults experts for potential concerns, for August 20. FDA panels usually cause significant price swings in the stock in the company under evaluation — so much so that trading is halted for the entire day that the panel takes place. Due to the potentially huge price swing in Jazz’s stock, I wanted to address what I thought was especially important for investors (and speculators!) to know heading into this event.
JAZZ: Your FDA Panel Primer
Rockford Coscia submits:
Jazz Pharmaceuticals (JAZZ) is a small biotech firm specializing in treatments for neurology and psychiatry patients. Jazz has two products currently being marketed in the U.S.: Xyrem for the treatment of narcolepsy, and Luvox CR for the treatment of social anxiety disorder and obsessive compulsive disorder. Currently, a new drug application is under review for Jazz’s fibromyalgia therapy currently referred to as JZP-6.
As part of the evaluation process, the FDA has scheduled a panel, in which it consults experts for potential concerns, for August 20. FDA panels usually cause significant price swings in the stock in the company under evaluation — so much so that trading is halted for the entire day that the panel takes place. Due to the potentially huge price swing in Jazz’s stock, I wanted to address what I thought was especially important for investors (and speculators!) to know heading into this event.
Next Page »
